COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome
Yıl: 2021 Cilt: 22 Sayı: 6 Sayfa Aralığı: 501 - 506 Metin Dili: İngilizce DOI: 10.5152/TurkThoracJ.2021.20329 İndeks Tarihi: 02-01-2022
COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428-455. [CrossRef]
- 2. Öztürk AB, Bavbek S. Role of SARS-CoV-2 in asthma exacerbations. Asthma Allergy Immunol. 2020;18. [CrossRef]
- 3. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. [CrossRef]
- 4. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. [CrossRef]
- 5. Hartmann-Boyce J, Gunnell J, Drake J, et al. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evid Based Med. 2020:bmjebm-2020-111506. [CrossRef]
- 6. Ozturk AB, Baççıoğlu A, Soyer O, et al. Change in allergy practice during the COVID-19 pandemic. Int Arch Allergy Immunol. 2021;182(1): 49-52. [CrossRef]
- 7. Vultaggio A, Agache I, Akdis CA, et al. Considerations on BioLogicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy. 2020;75(11):2764-2774. [CrossRef]
- 8. Turkish Ministry of Health. Covid-19 (Sars-Cov-2 infection) Guide: Study of Scientific Board. Available at: https ://hs gm.sa glik. gov.t r/dep o/bir imler /goc_ sagli gi/co vid19 /rehb er/CO VID-1 9_Reh beri2 02004 14_en g_v4_ 002_1 4.05. 2020. pdf. Accessed March 3, 2021.
- 9. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention.Updated 2020. Available at: https ://gi nasth ma.or g/wp- conte nt/up loads /2020 /04/G INA-2 020-f ull-r eport -fin al-_w ms.pd f. Accessed March 4, 2021.
- 10. Öztürk AB, Çağlayan B. Angiotensin converting Enzyme-2 (ACE2) Receptors, asthma and severe COVID-19 infection risk. Eur Ann Allergy Clin Immunol. 2020;52(6):282-285. [CrossRef]
- 11. Roncati L, Nasillo V, Lusenti B, Riva G. Signals of Th2 immune response from COVID-19 patients requiring intensive care. Ann Hematol. 2020;99(6):1419-1420. [CrossRef]
- 12. Edwards MR, Strong K, Cameron A, et al. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017;140(4):909-920. [CrossRef]
- 13. Hussein MH, Elshazli RM, Attia AS, et al. Asthma and COVID- 19; different entities, same outcome: a meta-analysis of 107,983 patients. J Asthma. 2021:1-8. [CrossRef]
- 14. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients With COVID-19. Chest. 2020;158(6):2290-2291. [CrossRef]
- 15. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? Allergy. 2021;76(3):866-868. [CrossRef]
- 16. Muñoz X, Pilia F, Ojanguren I, Romero-Mesones C, Cruz MJ. Is asthma a risk factor for COVID-19? Are phenotypes important? ERJ Open Res. 2021;7(1):00216-2020. [CrossRef]
- 17. Timberlake D. T., Strothman K., Grayson M. H. Asthma, severe acute respiratory syndrome coronavirus-2 and coronavirus disease 2019. Curr Opin Allergy Clin Immunol. 2021;21(2):182- 187. [CrossRef]
- 18. Maes T, Bracke K, Brusselle GG. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2020;202(1):8-10. [CrossRef]
- 19. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5). [CrossRef]
- 20. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9(7):699- 711. [CrossRef]
- 21. Eger K, Hashimoto S, Braunstahl GJ, et al. Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respir Med. 2020;177:106287. [CrossRef]
- 22. Domínguez-Ortega J, López-Carrasco V, Barranco P, et al. Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapy. J Allergy Clin Immunol Pract. 2020;8(8):2784-2786. [CrossRef]
- 23. Rial MJ, Valverde M, Del Pozo V, et al. Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. J Allergy Clin Immunol Pract. 2021;9(1):487-489.e1. [CrossRef]
- 24. Antonicelli L, Tontini C, Manzotti G, et al. Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: results from the Italian Severe Asthma Registry. Allergy. 2021;76(3):902-905. [CrossRef]
| APA | Sönmez S, KISAKUREK Z, Ozturk A, Tekin S (2021). COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. , 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| Chicago | Sönmez Sadi Can,KISAKUREK ZEYNEP BUSRA,Ozturk Ayse Bilge,Tekin Suda COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. (2021): 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| MLA | Sönmez Sadi Can,KISAKUREK ZEYNEP BUSRA,Ozturk Ayse Bilge,Tekin Suda COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. , 2021, ss.501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| AMA | Sönmez S,KISAKUREK Z,Ozturk A,Tekin S COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. . 2021; 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| Vancouver | Sönmez S,KISAKUREK Z,Ozturk A,Tekin S COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. . 2021; 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| IEEE | Sönmez S,KISAKUREK Z,Ozturk A,Tekin S "COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome." , ss.501 - 506, 2021. 10.5152/TurkThoracJ.2021.20329 |
| ISNAD | Sönmez, Sadi Can vd. "COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome". (2021), 501-506. https://doi.org/10.5152/TurkThoracJ.2021.20329 |
| APA | Sönmez S, KISAKUREK Z, Ozturk A, Tekin S (2021). COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. Turkish Thoracic Journal, 22(6), 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| Chicago | Sönmez Sadi Can,KISAKUREK ZEYNEP BUSRA,Ozturk Ayse Bilge,Tekin Suda COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. Turkish Thoracic Journal 22, no.6 (2021): 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| MLA | Sönmez Sadi Can,KISAKUREK ZEYNEP BUSRA,Ozturk Ayse Bilge,Tekin Suda COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. Turkish Thoracic Journal, vol.22, no.6, 2021, ss.501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| AMA | Sönmez S,KISAKUREK Z,Ozturk A,Tekin S COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. Turkish Thoracic Journal. 2021; 22(6): 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| Vancouver | Sönmez S,KISAKUREK Z,Ozturk A,Tekin S COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. Turkish Thoracic Journal. 2021; 22(6): 501 - 506. 10.5152/TurkThoracJ.2021.20329 |
| IEEE | Sönmez S,KISAKUREK Z,Ozturk A,Tekin S "COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome." Turkish Thoracic Journal, 22, ss.501 - 506, 2021. 10.5152/TurkThoracJ.2021.20329 |
| ISNAD | Sönmez, Sadi Can vd. "COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome". Turkish Thoracic Journal 22/6 (2021), 501-506. https://doi.org/10.5152/TurkThoracJ.2021.20329 |
